Cost-effectiveness analysis shows biosimilar ustekinumab could improve treatment strategies in Spain, indicating better patient access.
Positioning bsUST as a first line of treatment appears to be cost effective and an efficient alternative from the NHS perspective in Spain. Additionally, none of the alternative sequences proved to be cost effective compared with the sequence starting with bsADA-bsUST. bsUST may significantly impact Crohn's disease management in Spain, improving patient access due to its lower drug acquisition costs.
No takes yet. Share an insight, caveat, or question.
Rodríguez-Lago et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: